sGC stimulator

This article reviews the ViVA trial assessing vericiguat, an sGC stimulator, in angina patients with coronary vasospasm but no obstructive coronary artery disease. The study found no significant improvement in vasodilator function or angina symptoms, though vericiguat was well tolerated.